Reactor produced [ 64 Cu]CuCl 2 as a PET radiopharmaceutical for cancer imaging: from radiochemistry laboratory to nuclear medicine clinic

ConclusionsTo the best of our knowledge, this is the first study on use of reactor produced [64Cu]CuCl2 for PET imaging of cancer in human patients. It is envisaged that this route of production of64Cu would aid towards affordable availability of this radioisotope for widespread clinical use in countries with limited cyclotron facilities. (Source: Annals of Nuclear Medicine)

Feed Item Url: